HK1212628A1 - 用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑 - Google Patents

用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑

Info

Publication number
HK1212628A1
HK1212628A1 HK16100682.5A HK16100682A HK1212628A1 HK 1212628 A1 HK1212628 A1 HK 1212628A1 HK 16100682 A HK16100682 A HK 16100682A HK 1212628 A1 HK1212628 A1 HK 1212628A1
Authority
HK
Hong Kong
Prior art keywords
cxcl11
cxcl13
cxcl9
cxcr5
cxcl10
Prior art date
Application number
HK16100682.5A
Other languages
English (en)
Inventor
．利拉德 詹姆斯．
Original Assignee
Jyant Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jyant Tech filed Critical Jyant Tech
Publication of HK1212628A1 publication Critical patent/HK1212628A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
HK16100682.5A 2012-06-27 2016-01-21 用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑 HK1212628A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Publications (1)

Publication Number Publication Date
HK1212628A1 true HK1212628A1 (zh) 2016-06-17

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100682.5A HK1212628A1 (zh) 2012-06-27 2016-01-21 用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑

Country Status (5)

Country Link
EP (1) EP2866830A4 (zh)
JP (1) JP2015524793A (zh)
CN (2) CN104870013A (zh)
HK (1) HK1212628A1 (zh)
WO (1) WO2014003742A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459971B (zh) * 2014-04-08 2019-08-16 弗劳恩霍夫应用研究促进协会 用于治疗自身免疫性疾病的联合疗法
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
EP3714891B1 (en) 2017-11-24 2024-02-14 Seoul National University R&DB Foundation Anti-inflammatory composition comprising graphene nano-structure
CN110511912B (zh) * 2018-08-30 2024-03-22 浙江煦顼技术有限公司 免疫细胞的功能调节
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
WO2021026362A1 (en) * 2019-08-07 2021-02-11 Edifice Health, Inc. Treatment of prevention of cardiovascular disease
EP3960861A1 (en) * 2020-08-31 2022-03-02 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers that target cxcl9
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
TW202345871A (zh) * 2022-03-30 2023-12-01 美商旗艦先鋒創新公司 Cxcl調節組合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011218A1 (en) * 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
SG10201407388XA (en) * 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
CN103347896B (zh) * 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
EP2652508B1 (en) * 2010-12-14 2018-02-07 Jyant Technologies, Inc. The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Also Published As

Publication number Publication date
CN104870013A (zh) 2015-08-26
EP2866830A1 (en) 2015-05-06
CN112807427A (zh) 2021-05-18
WO2014003742A1 (en) 2014-01-03
JP2015524793A (ja) 2015-08-27
EP2866830A4 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
HK1212628A1 (zh) 用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
RS58892B1 (sr) Jedinjenja 3-aminocikloalkila kao inhibitori ror-gama-t i njihove upotrebe
GB2508204B (en) Orthosis
HK1212625A1 (zh) 用於炎性疾病的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
EP2895609A4 (en) METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
EP2909214A4 (en) DERIVATIVES OF ETOPOSIDE
ZA201402475B (en) Self-adhesive lavatory treatment compositions
HK1207078A1 (zh) 酶的抑制
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
HK1206264A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法
EP4144845C0 (en) ANTISENSE COMPOUNDS AND THEIR USES
EP2858648A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING PIN1
EP2828241A4 (en) COMPOSITIONS AND METHOD FOR INHIBITING CATHEPSINES
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL236138A (en) Dipluoro-hexahydro-cyclophenoxazinyls and diplooro-hexahydro-benzooxazinyls as bace inhibitors1
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
HK1209422A1 (zh) 抑制劑
HK1209639A1 (zh) 的抑制及其治療用途
LT2858606T (lt) Įtvaras
HK1201066A1 (zh) 端錨聚合酶的吡喃並吡啶酮抑制劑
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
EP2931746A4 (en) METHOD AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRUCTURED RNA
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
HK1205500A1 (zh) 用於癌症治療的激酶抑制劑
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR